Literature DB >> 22986456

Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism.

Michiko Takahashi1, Sumie Inomata, Yasuhiko Okimura, Genzo Iguchi, Hidenori Fukuoka, Kazuaki Miyake, Daisuke Koga, Suguru Akamatsu, Masato Kasuga, Yutaka Takahashi.   

Abstract

Chemerin, a recently discovered adipocytokine plays an important role in obesity and obesity-associated metabolic complications. However, the role of chemerin in the pathogenesis of type 2 diabetes mellitus (T2DM) has not fully been elucidated. We compared the serum chemerin levels and metabolic parameters between 88 control subjects, 86 patients with metabolic syndrome (MS), and 147 patients with T2DM in a Japanese population and further analyzed their correlation. Enzyme-linked immunosorbent assay was used to measure the serum chemerin levels. The chemerin levels were significantly higher in male than in female control subjects (p < 0.005), with significant decreases in patients with T2DM compared with those with MS and control subjects (164.9 ± 6.3 ng/mL vs. 209.8 ± 7.7 and 218.7 ± 7.3 ng/mL; p < 0.0001 vs. p < 0.0001, respectively) but no significant differences in female subjects. The multiple regression analysis revealed that the chemerin levels negatively correlated with the fasting glucose and HbA1c levels in total and male subjects. In the patients with T2DM, the chemerin levels negatively correlated with fasting glucose and high-density lipoprotein cholesterol but positively correlated with body mass index (BMI), and total cholesterol and triglyceride levels. The negative correlation between the chemerin and fasting glucose levels remained significant after adjustment for age, sex, and BMI in the total and male subjects and those with T2DM. These results suggest the role of chemerin in sex dimorphism and a potential link between chemerin levels and T2DM pathogenesis in a Japanese population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22986456     DOI: 10.1507/endocrj.ej12-0201

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  12 in total

1.  Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis.

Authors:  Ya Li; Bingyin Shi; Sheli Li
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

2.  The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Authors:  Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

3.  Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Erifili Hatziagelaki; Christian Herder; Anastasia Tsiavou; Tom Teichert; Athina Chounta; Peter Nowotny; Giovanni Pacini; George Dimitriadis; Michael Roden
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

4.  Evaluation of circulating adipokines and abdominal obesity as predictors of significant myocardial ischemia using gated single-photon emission computed tomography.

Authors:  Chi-Sheng Hung; Yen-Wen Wu; Jei-Yie Huang; Pei-Ying Hsu; Ming-Fong Chen
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

5.  Serum Chemerin Levels Are Associated with Abdominal Visceral Fat in Type 2 Diabetes.

Authors:  Juyoung Han; So Hun Kim; Young Ju Suh; Hyun Ae Lim; Heekyoung Shin; Soon Gu Cho; Chei Won Kim; Seung Youn Lee; Dae Hyung Lee; Seongbin Hong; Yong Seong Kim; Moon-Suk Nam
Journal:  J Korean Med Sci       Date:  2016-04-26       Impact factor: 2.153

6.  CMKLR1 activation ex vivo does not increase proportionally to serum total chemerin in obese humans.

Authors:  Jay Toulany; Sebastian D Parlee; Christopher J Sinal; Kathryn Slayter; Shelly McNeil; Kerry B Goralski
Journal:  Endocr Connect       Date:  2016-11-08       Impact factor: 3.335

7.  Chemerin is not associated with subclinical atherosclerosis markers in prediabetes and diabetes.

Authors:  Kadriye Aydın; Uğur Canpolat; Şafak Akın; Muhammet Dural; Jale Karakaya; Kudret Aytemir; Necla Özer; Alper Gürlek
Journal:  Anatol J Cardiol       Date:  2015-11-26       Impact factor: 1.596

Review 8.  Chemerin: a multifaceted adipokine involved in metabolic disorders.

Authors:  Gisela Helfer; Qing-Feng Wu
Journal:  J Endocrinol       Date:  2018-05-30       Impact factor: 4.286

9.  Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis.

Authors:  Paul Horn; Christian von Loeffelholz; Franziska Forkert; Sven Stengel; Philipp Reuken; René Aschenbach; Andreas Stallmach; Tony Bruns
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

10.  Independent Association of Circulating Level of Chemerin With Functional and Early Morphological Vascular Changes in Newly Diagnosed Type 2 Diabetic Patients.

Authors:  Bin Lu; Ming Zhao; Weimin Jiang; Jian Ma; Cuihua Yang; Jiaqing Shao; Ping Gu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.